Compare ADUS & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADUS | INSP |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2009 | 2018 |
| Metric | ADUS | INSP |
|---|---|---|
| Price | $93.23 | $44.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 16 |
| Target Price | ★ $133.78 | $94.00 |
| AVG Volume (30 Days) | 252.5K | ★ 1.1M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.40 | ★ 179.43 |
| EPS | ★ 1.36 | N/A |
| Revenue | N/A | ★ $82,050,000.00 |
| Revenue This Year | $9.17 | $8.02 |
| Revenue Next Year | $4.70 | $8.11 |
| P/E Ratio | $68.84 | ★ N/A |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $89.76 | $39.61 |
| 52 Week High | $124.44 | $147.66 |
| Indicator | ADUS | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 41.41 |
| Support Level | $91.12 | N/A |
| Resistance Level | $96.07 | $59.40 |
| Average True Range (ATR) | 3.91 | 2.82 |
| MACD | -0.43 | -0.04 |
| Stochastic Oscillator | 25.22 | 28.31 |
Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.